TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Protagenic Therapeutics ( (PTIX) ) just unveiled an update.
Protagenic Therapeutics is addressing a delay in filing its quarterly report for June 2025, which resulted in a Nasdaq compliance notice. The company plans to resolve this within 60 days, ensuring its securities remain unaffected. Additionally, Protagenic has completed the first dose injections in its Phase I trial for PT00114, with results expected by September 2025, paving the way for Phase 2 studies in early 2026.
Spark’s Take on PTIX Stock
According to Spark, TipRanks’ AI Analyst, PTIX is a Underperform.
Protagenic Therapeutics faces significant financial difficulties, with no revenue and persistent losses. Technical indicators suggest weak market momentum, and the company’s valuation is unattractive due to negative earnings. These factors collectively result in a low overall stock score, reflecting substantial risks and challenges.
To see Spark’s full report on PTIX stock, click here.
More about Protagenic Therapeutics
Protagenic Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of therapeutic products. The company is engaged in clinical trials to advance its primary product, PT00114, which is undergoing Phase I trials with plans to move into Phase 2 efficacy studies.
Average Trading Volume: 203,682
Technical Sentiment Signal: Sell
Current Market Cap: $2.22M
Learn more about PTIX stock on TipRanks’ Stock Analysis page.